Rosa Coelho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rosa Coelho has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Guilherme Macedo
Department of Gastroenterology, São João University Hospital, 4200-319 Porto, Portugal
2 shared publications - Ana Margarida Sobrinho Ribeiro
Serviço de Psiquiatria, Unidade Local de Saúde de Trás‑os‑Montes e Alto Douro, Vila Real, Portugal
1 shared publication - Ana Teresa Caldeira
HERCULES Laboratory, IN2PAST—Associate Laboratory for Research and Innovation in Heritage, Arts, Sustainability and Territory, University of Évora, Largo Marquês de Marialva 8, 7000-809 Évora, Portugal
1 shared publication - Bárbara Morão
Division of Gastroenterology Hospital Beatriz Ângelo Loures Portugal
1 shared publication - Carolina Palmela
Gastroenterology Division, Hospital Beatriz Ângelo, Unidade Local de Saúde de Loures/Odivelas, Portugal
1 shared publication - Catarina Frias Gomes
Division of Gastroenterology, Hospital Beatriz Ângelo , Loures , Portugal
1 shared publication
Latest Publications
- Open Access
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (Supplement) , S487
P505 Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound
Therapeutic drug monitoring (TDM) in patients receiving infliximab (IFX) has a role in assessing treatment and managing outcomes. Infliximab trough levels (ITL) have been suggested as useful markers for treatment optimization in Crohn’s disease (CD).Our goals were: to assess the relationship between ITL and transmural inflammation as assessed by intestinal ultrasound(IUS), following induction therapy with IFX; to assess which clinical, laboratorial or IUS parameters better predicted adequate levels by the end of induction therapy. Prospective multicentric cohort study including patients with active CD starting IFX therapy. Clinical disease activity assessed using the Harvey-Bradshaw index (HBI), C-reactive protein (CRP), fecal calprotectin (FC) were measured at week 0 and after induction therapy (week 14). IUS was performed at week 0 and 14, bowel wall thickness (BWT) from the worst segment was selected for analysis. Ileocolonoscopy was performed at W0 and SES-CD was registered. ITL were measured at W14. We included 36 patients with CD (61% male; median age 30 years (range 16–73)). According to Montreal classification, most patients were A2 (69%), had ileocolonic disease (L3 56%) and an inflammatory phenotype (B1 58%).Perianal disease was present in 42%. Combination therapy was used in 61%. After induction therapy, 81% were in clinical remission (HBI 25% in BWT) was observed in 24% of patients and remission (BWT normalization) in 11%. Median ITL were 4.3 (IQR 2.3–8.1) and 64% had ITL >3 ug/ml. There was a good negative correlation between ITL and SES-CD (r=-0.492, p=0.003). Adequate ITL were associated with lower HBI (1.5 vs 4.5, p=0.052), laboratory remission (61% vs 15%, p=0.014), lower BWT (4 vs 5.5 mm, p=0.009) and sonographic response (39% vs 0%, p=0.014) at W14. At the end of induction, we found a fair to good correlation between ITL and HBI (r=-0.430, p=0.009),CRP (r=-0,510, p=0.001), FC (r=-0.590, p=0.001) and BWT (R=-0.506, p=0.002). Receiver operating characteristic (ROC) curve analysis showed that FC at W14 had the largest area under the curve (AUC) in predicting adequate ITL (0.813 vs 0.716 vs 0.739 vs 0.772, p<0.05). Patients with higher disease burden measured by ileocolonoscopy at baseline had lower ITL after induction. Adequate ITL were associated with laboratorial remission and sonographic response at the end of induction, with a good correlation with clinical, laboratorial and sonographic parameters. These findings suggest that adequate IFX levels after induction are associated with a better control of inflammation in IBD, so early proactive TDM during induction may be helpful in treatment management.
- 1 May 2021
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (Supplement) , S487
Open AccessP505 Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound
Therapeutic drug monitoring (TDM) in patients receiving infliximab (IFX) has a role in assessing treatment and managing outcomes. Infliximab trough levels (ITL) have been suggested as useful markers for treatment optimization in Crohn’s disease (CD).Our goals were: to assess the relationship between ITL and transmural inflammation as assessed by intestinal ultrasound(IUS), following induction therapy with IFX; to assess which clinical, laboratorial or IUS parameters better predicted adequate levels by the end of induction therapy. Prospective multicentric cohort study including patients with active CD starting IFX therapy. Clinical disease activity assessed using the Harvey-Bradshaw index (HBI), C-reactive protein (CRP), fecal calprotectin (FC) were measured at week 0 and after induction therapy (week 14). IUS was performed at week 0 and 14, bowel wall thickness (BWT) from the worst segment was selected for analysis. Ileocolonoscopy was performed at W0 and SES-CD was registered. ITL were measured at W14. We included 36 patients with CD (61% male; median age 30 years (range 16–73)). According to Montreal classification, most patients were A2 (69%), had ileocolonic disease (L3 56%) and an inflammatory phenotype (B1 58%).Perianal disease was present in 42%. Combination therapy was used in 61%. After induction therapy, 81% were in clinical remission (HBI 25% in BWT) was observed in 24% of patients and remission (BWT normalization) in 11%. Median ITL were 4.3 (IQR 2.3–8.1) and 64% had ITL >3 ug/ml. There was a good negative correlation between ITL and SES-CD (r=-0.492, p=0.003). Adequate ITL were associated with lower HBI (1.5 vs 4.5, p=0.052), laboratory remission (61% vs 15%, p=0.014), lower BWT (4 vs 5.5 mm, p=0.009) and sonographic response (39% vs 0%, p=0.014) at W14. At the end of induction, we found a fair to good correlation between ITL and HBI (r=-0.430, p=0.009),CRP (r=-0,510, p=0.001), FC (r=-0.590, p=0.001) and BWT (R=-0.506, p=0.002). Receiver operating characteristic (ROC) curve analysis showed that FC at W14 had the largest area under the curve (AUC) in predicting adequate ITL (0.813 vs 0.716 vs 0.739 vs 0.772, p<0.05). Patients with higher disease burden measured by ileocolonoscopy at baseline had lower ITL after induction. Adequate ITL were associated with laboratorial remission and sonographic response at the end of induction, with a good correlation with clinical, laboratorial and sonographic parameters. These findings suggest that adequate IFX levels after induction are associated with a better control of inflammation in IBD, so early proactive TDM during induction may be helpful in treatment management.
- 8 October 2016
- Published by Morressier GmbH
RESECTABLE PANCREATIC CANCER: ARE WE PERFORMING A GOOD PRE-OPERATIVE STAGING?
- 8 October 2016
- Published by Morressier GmbH
RESECTABLE PANCREATIC CANCER: ARE WE PERFORMING A GOOD PRE-OPERATIVE STAGING?
- 8 October 2016
- Published by Morressier GmbH
ERECTIL (DYS)FUNCTION IN PATIENTS WITH LIVER CIRRHOSIS: A CROSS-SECTIONAL STUDY
- 8 October 2016
- Published by Morressier GmbH
ERECTIL (DYS)FUNCTION IN PATIENTS WITH LIVER CIRRHOSIS: A CROSS-SECTIONAL STUDY
- 8 October 2016
- Published by Morressier GmbH
SEXUAL DYSFUNCTION IN CHRONIC LIVER DISEASE: IS IT A HOT TOPIC FOR CIRRHOTIC PATIENTS?
- 8 October 2016
- Published by Morressier GmbH
SEXUAL DYSFUNCTION IN CHRONIC LIVER DISEASE: IS IT A HOT TOPIC FOR CIRRHOTIC PATIENTS?
- 8 October 2016
- Published by Morressier GmbH
ALBI SCORE: BEST PREDICTOR OF SHORT-TERM MORTALITY IN HEPATOCELLULAR CARCINOMA
- 8 October 2016
- Published by Morressier GmbH
ALBI SCORE: BEST PREDICTOR OF SHORT-TERM MORTALITY IN HEPATOCELLULAR CARCINOMA
- 8 October 2016
- Published by Morressier GmbH
INGESTED FOREIGN BODIES AND FOOD IMPACTIONS: RETROSPECTIVE ANALYSIS OF 383 CASES
- 8 October 2016
- Published by Morressier GmbH
INGESTED FOREIGN BODIES AND FOOD IMPACTIONS: RETROSPECTIVE ANALYSIS OF 383 CASES
- 15 September 2016
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 30 (3) , 1-6
Outcome and risk factors assessment for adverse events in advanced esophageal cancer patients after self-expanding metal stents placement
Self-expanding metal stents (SEMS) are the treatment of choice for advanced esophageal cancers. Literature is scarce on risk factors predictors for adverse events after SEMS placement. Assess risk factors for adverse events after SEMS placement in advanced esophageal cancer and evaluate survival after SEMS placement. Cross-sectional study of patients with advanced esophageal cancer referred for SEMS placement, during a period of 3 years. Ninety-seven patients with advanced esophageal cancer placed SEMS. Adverse events were more common when tumors were located at the level of the distal esophagus/cardia (47% vs 23%, P = 0.011, OR 3.1), with statistical significance being kept in the multivariate analysis (OR 3.1, P = 0.018). Time until adverse events was lower in the tumors located at the level of the distal esophagus/cardia (P = 0.036). Survival was higher in patients who placed SEMS with curative intent (327 days [126–528] vs. 119 days [91–147], P = 0.002) and in patients submitted subsequently to surgery compared with those who did just chemo/radiotherapy or who did not do further treatment (563 days [378–748] vs. 154 days [133–175] vs. 46 days [20–72], P < 0.001). Subsequent treatment kept statistical significance in the multivariate analysis (HR 3.4, P < 0.001). SEMS allow palliation of dysphagia in advanced esophageal cancer and are associated with an increased out-of-hospital survival, as long as there are conditions for further treatments. Tumors located at the level of the distal esophagus/cardia are associated with a greater number of adverse events, which also occur earlier.
- 15 September 2016
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 30 (3) , 1-6
Outcome and risk factors assessment for adverse events in advanced esophageal cancer patients after self-expanding metal stents placement
Self-expanding metal stents (SEMS) are the treatment of choice for advanced esophageal cancers. Literature is scarce on risk factors predictors for adverse events after SEMS placement. Assess risk factors for adverse events after SEMS placement in advanced esophageal cancer and evaluate survival after SEMS placement. Cross-sectional study of patients with advanced esophageal cancer referred for SEMS placement, during a period of 3 years. Ninety-seven patients with advanced esophageal cancer placed SEMS. Adverse events were more common when tumors were located at the level of the distal esophagus/cardia (47% vs 23%, P = 0.011, OR 3.1), with statistical significance being kept in the multivariate analysis (OR 3.1, P = 0.018). Time until adverse events was lower in the tumors located at the level of the distal esophagus/cardia (P = 0.036). Survival was higher in patients who placed SEMS with curative intent (327 days [126–528] vs. 119 days [91–147], P = 0.002) and in patients submitted subsequently to surgery compared with those who did just chemo/radiotherapy or who did not do further treatment (563 days [378–748] vs. 154 days [133–175] vs. 46 days [20–72], P < 0.001). Subsequent treatment kept statistical significance in the multivariate analysis (HR 3.4, P < 0.001). SEMS allow palliation of dysphagia in advanced esophageal cancer and are associated with an increased out-of-hospital survival, as long as there are conditions for further treatments. Tumors located at the level of the distal esophagus/cardia are associated with a greater number of adverse events, which also occur earlier.